Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial
Primary result · Target lesion failureResult — go to the resultRisk difference −0.83 percentage pointsAuthors' conclusion
In patients with diabetes and multivessel disease undergoing percutaneous coronary intervention, ultra-thin biodegradable polymer SES was noninferior to durable polymer EES at 1 year follow-up.
Study context
- Population
- Patients with diabetes and multivessel disease undergoing PCI
- Participants
- 1,800 patients
- Comparison
- Ultra-thin BP-SES vs DP-EES
- Primary endpoint
- Target lesion failure:
- Cardiac death
- Target vessel MI
- Ischemia-driven target lesion revascularization
- Follow-up
- 1 year
Methodological detailsinvestigator-initiated, prospective, open-label, multicentre, 2 × 2 factorial, non-inferiority, Patients also randomised to ticagrelor or prasugrel
- Investigator-initiated
- Prospective
- Open-label
- Multicentre
- 2 × 2 factorial
- Non-inferiority
- Patients also randomised to ticagrelor or prasugrel
Primary result
Target lesion failure
Risk difference
−0.83 percentage points
PNI = 0.005
Events by treatment group
As reported in the abstract
Further findings
Components of target lesion failure · 1 year
- Cardiac death, BP-SES vs DP-EES (no significant difference)
- 3.6% vs 3.4%
- Target vessel MI, BP-SES vs DP-EES (no significant difference)
- 6.61% vs 7.54%
- Ischemia-driven target lesion revascularization, BP-SES vs DP-EES (no significant difference)
- 0.8% vs 1.0%
Nonfatal MI · 1 year
- Nonfatal MI, BP-SES vs DP-EES (similar)
- 4.7% vs 6.4%
Safety
Stent thrombosis · 1 year
- Stent thrombosis, BP-SES vs DP-EES (similar)
- 1.0 % vs 0.7%
Original publication
Ultra-Thin Sirolimus-Eluting Versus Everolimus-Eluting Stents in Diabetic Multivessel Coronary Artery Disease Patients: The TUXEDO-2 Trial. J Am Coll Cardiol. Published 1 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it